Changes in 49c8c06: add clinical section

				XPO1.md
			
          @@ -15,7 +15,7 @@ In DLBCL, mutations at the canonical hotspot (E571) have been experimentally dem

           ## Clinical Relevance

          -Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) *for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.*.

          +Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) *for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.*. Importantly, eligibility does not depend on the presence of mutations in XPO1. 

           ## Relevance tier by entity

...	...	@@ -15,7 +15,7 @@ In DLBCL, mutations at the canonical hotspot (E571) have been experimentally dem
15	15
16	16	## Clinical Relevance
17	17
18		-Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy..
	18	+Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.. Importantly, eligibility does not depend on the presence of mutations in XPO1.
19	19
20	20	## Relevance tier by entity
21	21